Du är här


Novartis International AG: Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries

Novartis International AG / Novartis launches 'Novartis Access', a portfolio
of affordable medicines totreat chronic diseases in lower-income countries .
Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is
solely responsible for the content of this announcement.
* First-of-its-kind portfolio approach in healthcare industry, aiming to
increase availability and affordability of 15 medicines against
cardiovascular diseases, diabetes, respiratory illnesses and breast cancer
* Novartis portfolio to be offered to governments and non-governmental
organizations in low- and low-middle-income countries for USD 1 per
treatment, per month
* Some 28 million people die from chronic diseases in low- and middle-income
countries each year, representing 75% of such deaths globally[1]

The digital press release with multimedia content can be accessed here:

New York, September 24, 2015
- Novartis today announced the launch of Novartis Access, a portfolio of 15
medicines to treat chronic diseases in low- and low-middle-income countries.
The portfolio addresses cardiovascular diseases, diabetes, respiratory
illnesses, and breast cancer and will be offered to governments,
non-governmental organizations (NGOs) and other public-sector healthcare
providers for USD 1 per treatment, per month.

"Novartis Access is a natural extension of two important contributions our
company makes to society: developing innovative medicines that help people
fight disease and working to get them to as many people as possible," said
Joerg Reinhardt, Chairman of the Board of Novartis. "This program takes an
novel approach to addressing the rising tide of chronic diseases in parts of
the world where people often have limited access to healthcare. We know we
will need to keep an open mindset and learn as we progress on this journey."

The Novartis Access portfolio includes patented and generic Novartis
medicines. It will be launched first in Kenya, Ethiopia and Vietnam. Over the
coming years, Novartis plans to roll out Novartis Access to 30 countries,
depending on demand.

The products included in the Novartis Access product portfolio have been
selected based on the World Health Organization's Essential Medicines List
and are among the most commonly prescribed medicines in these countries.
Novartis expects this new approach to be commercially sustainable over the
long term, enabling continuous support in those regions.

Each year, approximately 28 million people die from chronic noncommunicable
diseases (NCDs) in low- and middle-income countries, representing 75% of
deaths from NCDs globally[1]. By 2025, the WHO projects that 75% of all
deaths will be due to NCDs[2], mostly due to the rapid increase of NCDs in
poverty-stricken areas.

Novartis is launching Novartis Access to coincide with the United Nations
Sustainable Development Summit 2015, where the new Sustainable Development
Goals will be adopted.

To more effectively address the rapid rise of chronic diseases in low- and
low-middle-income countries, Novartis is actively seeking to partner with
governments, NGOs and other public-sector organizations to strengthen
healthcare systems. Areas of potential collaboration include programs to
raise awareness about diseases, train healthcare workers to diagnose and
treat chronic illnesses and strengthen medicine distribution systems.

The challenge of improving access to medicines and healthcare will take a
concerted long-term effort by many people and organizations. As a healthcare
company, Novartis is trying to do its part.


This press release contains expressed or implied forward-looking
statements, including statements that can be identified by terminology such
as "launches," "to treat," "aiming," "to be offered," "launch," "will,"
"plans," "expects," "potential," or similar expressions. Such forward-looking
statements reflect the current views of the Group regarding future events,
and involve known and unknown risks, uncertainties and other factors that may
cause actual results to be materially different from any future results
expressed or implied by such statements. These expectations could be affected
by, among other things, risks and factors referred to in the Risk Factors
section of Novartis AG's current Form 20-F on file with the US Securities and
Exchange Commission. Novartis is providing the information in this press
release as of this date and does not undertake any obligation to update it in
the future.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland,
Novartis offers a diversified portfolio to best meet these needs: innovative
medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the
only global company with leading positions in these areas. In 2014, the Group
achieved net sales of USD 58.0 billion, while R&D throughout the Group
amounted to approximately USD 9.9 billion (USD 9.6 billion excluding
impairment and amortization charges). Novartis Group companies employ
approximately 120,000 full-time-equivalent associates. Novartis products are
available in more than 180 countries around the world. For more information,
please visithttp://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis


[1] World Health Organization, "Noncommunicable diseases fact sheet":
http://www.who.int/mediacentre/factsheets/fs355/en/, Accessed 14 September

[2] World Health Organization, "The Global Burden of Disease: Updated
http://www.who.int/healthinfo/global_burden_disease/en/, Accessed July 22,

# # #

Novartis Media Relations

| Central media line : |
|+41 61 324 2200 |
| Liz Power Nadine Schecker |
| |
|Novartis Global Media Relations Novartis Access Commuincations |
|1 212 830 2466 (direct) 41 61 696 8633 (direct) |
|1 617 583 3015 (mobile) 41 79 682 1326 (mobile) |
|elizabeth.power@novartis.com nadine.schecker@novartis.com |

For Novartis multimedia content, please visitwww.thenewsmarket.com/Novartis

For questions about the site or required registration, please

Novartis Investor Relations

| Central phone: +41 61 324 7944 |
| Samir Shah +41 61 324 7944 North America: |
| Pierre-Michel Bringer +41 61 324 1065 Richard Pulik +1 212 830 2448 |
| Thomas Hungerbuehler +41 61 324 8425 Sloan Pavsner +1 212 830 2417 |
| Isabella Zinck +41 61 324 7188 |
| |
| e-mail:investor.relations@novartis.com e-mail:investor.relations@novartis.com |

Media release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.